Oncolytic Virus Solutions for Specialized Environments
Legal Citation
Summary of the Inventive Concept
The present invention relates to specialized oncolytic virus solutions adapted for specific, narrow markets or unique operational environments, such as high-security facilities, disaster relief zones, extreme weather conditions, and remote areas.
Background and Problem Solved
The original patent disclosed a recombinant oncolytic virus with improved safety and anticancer effect. However, there remains a need for oncolytic virus solutions tailored to specific environments, where standard treatments may not be effective or feasible. The present invention addresses this limitation by providing novel solutions for delivering, tracking, and treating cancer in these specialized environments.
Detailed Description of the Inventive Concept
The inventive concept comprises four specialized solutions: (1) a system for delivering an oncolytic virus to a target site in a high-security facility, (2) a method for treating cancer in a patient in a disaster relief zone, (3) a kit for treating cancer in extreme weather conditions, and (4) a system for tracking the delivery of an oncolytic virus to a target site in a high-security facility, as well as a method for treating cancer in a patient in a remote area. Each solution incorporates a recombinant oncolytic virus comprising a nucleotide sequence encoding a truncated fragment of HSV1-TK or a variant thereof, as disclosed in the original patent.
Novelty and Inventive Step
The novelty of the present invention lies in the adaptation of the original oncolytic virus to specialized environments, which requires unique considerations for containment, delivery, tracking, and treatment. The inventive step resides in the combination of the original virus with novel components and methods tailored to these environments, resulting in solutions that are not obvious from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include varying the containment vessel design, delivery mechanism, or tracking device for different high-security facilities or disaster relief zones. Variations of the kit for extreme weather conditions may include different temperature-controlled storage containers or additional components for patient monitoring.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the fields of oncology, biotechnology, and healthcare, particularly in high-security facilities, disaster relief organizations, and remote area healthcare providers. The market for these specialized oncolytic virus solutions is expected to grow as the need for tailored treatments in unique environments increases.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K35/768 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K31/708 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/24111 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and medical virology, specifically oncolytic virus engineering and cancer treatment technologies. Requires advanced knowledge of genetic engineering, viral modification, and targeted therapeutic delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A researcher or biotechnology professional with advanced degrees in molecular biology, virology, or oncology, possessing expertise in genetic manipulation of viruses, understanding of viral vector design, and familiarity with targeted cancer therapies
Obviousness Rationale
A PHOSITA would recognize that adapting the core oncolytic virus technology to specialized delivery environments represents a predictable engineering variation. The fundamental viral construct remains consistent, with modifications focused on practical implementation and contextual adaptation. The technical solutions proposed are logical extensions of existing viral therapy deployment strategies that would be apparent to a skilled practitioner.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,585 |
|---|---|
| Title | Oncolytic virus improved in safety and anticancer effect |
| Assignee(s) | BIONOXX INC. |